New Leaf Venture Partners LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
New Leaf Venture Partners LLC
CRD #163897
SEC #801-80793
CIK #0001375661, 0001441439, 0001455617, 0001441858, 0001625696, 0001455597, 0001625656, 0001416362, 0001441857, 0001631614
AUM 408.4 M (2026-03-30)
Employees 4 (50% Investors, 0% Brokers)
Fees
Minimum
Phone646-871-6420
Address156 Fifth Avenue
New York, NY 10010
Source [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn]
Total AUM ($M)
110088066044022002010201520212027
Fees and Compensation — Form ADV Part 2A (3/30/2026) [Brochure]
Item 5 - Fees and Compensation

Compensation and Fee Schedules

New Leaf typically receives an advisory fee from each of the Funds, which is generally
equal to a percentage of the capital commitments to such Fund. The fee percentage and/or
the base upon which the fee is calculated may vary with the size of the Fund and may
also vary over the life of the Fund, as negotiated and determined at the time the Fund is
established and as set forth in its Governing Documents. In addition, a related person of
New Leaf, as general partner of a Fund, will typically receive certain allocations and
distributions calculated and charged based on a share of capital gains on or capital
appreciation of the assets of such Fund, as negotiated and determined at the time such
Fund is established and as set forth in its Governing Documents. These allocations and
distributions are commonly known as “carried interest.” Different Funds may be subject
to different management fees and performance-based compensation arrangements and
certain funds (such a co-investment funds) may not be subject to any advisory fees and/or
Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2026) [Brochure]
Types of Clients

New Leaf generally provides investment advice to pooled investment vehicles, such as
the Funds. The limited partners of (or investors in) the Funds may include corporations,
financial institutions, funds-of-funds, governmental bodies or agencies, insurance
companies, endowments, foundations, trusts, estates, high net worth individuals, and
pension and profit-sharing plans.

In connection with the formation and management of a Fund, New Leaf may form certain
related entities for such Fund. New Leaf may establish vehicles to address tax, legal or
regulatory issues or requirements of certain investors in such Fund or for other purposes.

New Leaf may also form “parallel funds” to invest alongside a Fund in all of its
investments. In addition, New Leaf may form “alternative investment vehicles” or
special purpose vehicles (collectively, “AIVs”) for the purpose of facilitating certain
investments by one or more Funds. Please refer to the Governing Documents of the
applicable Fund for more complete details on parallel funds and AIVs.

New Leaf may also provide investment management and supervisory services to separate
account clients.

Minimum Investment Requirements

Interests in the Funds are offered in private placements under the U.S. Securities Act of
1933, as amended (the “Securities Act”). As a result, New Leaf generally offers limited
partner (or equivalent) interests in the Funds to a limited number of “accredited
investors” as defined in Regulation D under the Securities Act and, in most cases,
exclusively to “qualified purchasers” as defined in Section 2(a)(51) of the U.S.
Investment Company Act of 1940, as amended.

In general, the minimum investment commitment required of an investor to participate in
a Fund is $5,000,000; however, the general partner of each Fund has discretion to
increase or reduce the minimum investment commitment. Investors and prospective
investors in each Fund should refer to the Governing Documents of such Fund for more
complete information on minimum investment requirements for participation in such
Fund.
Sector Form 13F Holdings Value ($M)
Edgewise Therapeutics Inc 16.7
Arvinas Inc 13.5
Crinetics Pharmaceuticals Inc 5.9
UNUM Therapeutics Inc 3.6
Rallybio Corp 1.6
Alector Inc 1.0
Passage Bio Inc 0.7
 
 
 
 
Holdings by Sector ($M)
60048036024012002013201720212026
Type Form D Funds Date Sold AUM
VC NLV Co-Invest IV LP [2025-03-31] 16.7 M 16.8 M
Offered $16,660,000 · Filed 2024-12-31 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable
VC NLV-II SPV-1 LP [2024-03-28] 90.8 M
VC NLV-II SPV-2 LP [2024-03-28] 9.0 M
Filed 2023-11-13 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Not Applicable
VC NLV Co-Invest III LLC 2022-03-30 9.0 M
VC NLV Co-Invest II LLC 2021-03-25 5.3 M
VC New Leaf Biopharma Opportunities II LP [2019-03-29] 120.7 M
Offered $200,000,000 · Filed 2018-04-16 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $200,000,000 · Duration One year or less · Revenue Not Applicable
VC New Leaf Ventures IV LP [2019-03-29] 94.4 M
Offered $275,000,000 · Filed 2018-04-16 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $275,000,000 · Duration One year or less · Finder's Fee $25,000 · Revenue Not Applicable
VC New Leaf Biopharma Opportunities I LP [2014-12-19] 10.0 M
Offered $200,000,000 · Filed 2014-12-04 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $200,000,000 · Duration One year or less · Revenue Not Applicable
VC New Leaf Ventures III LP [2014-12-19] 62.4 M
Offered $375,000,000 · Filed 2014-12-03 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $375,000,000 · Duration One year or less · Revenue Not Applicable
VC NLV Partners Co-Invest I LLC 2014-12-19 8.0 M
View All
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 9 408.4
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 9 408.4
By Discretionary
Discretionary 9 408.4
Non-Discretionary 0 0.0
Total 9 408.4
By Non-United States Persons
Non-United States Persons 0.0
United States Persons 408.4
Total 9 408.4
Limited Partners2011 - 2026
State of Michigan Retirement System
Form D Directors Role # Filings # Firms 2011 - 2026
Vijay Lathi Executive Officer 34 2
Jeani Delagardelle Executive Officer 32 2
Liam Ratcliffe Executive Officer 25 2
Ronald Hunt Executive Officer 25 2
Ron Hunt Executive Officer 19 2
Philippe Chambon Executive Officer 13 2
Isaac Manke Executive Officer 8 2
Nlv SPV GP LLC Executive Officer 3 2
New Leaf Venture Management III LLC Director 3 2
Craig Slutzkin Executive Officer 3 2
View All
EDGAR Form CIK 2011 - 2026
3 [0001375661]
4 [0001375661]
SC 13G [0001375661]
3 [0001441439]
4 [0001441439]
SC 13D [0001441439]
SC 13G [0001441439]
3 [0001441857]
4 [0001441857]
3 [0001441858]
4 [0001441858]
3 [0001455597]
4 [0001455597]
3 [0001455617]
4 [0001455617]
3 [0001625656]
4 [0001625656]
3 [0001625696]
4 [0001625696]
D [0001625696]
SC 13G [0001625696]
13F-HR [0001631614]
3 [0001631614]
4 [0001631614]
Form 13D/13G Filer Form 13D/13G Subject Filed
New Leaf Biopharma Opportunities I LP Addex Therapeutics Ltd [2021-02-10]
New Leaf Ventures II LP Principia Biopharma Inc [2019-02-13]
New Leaf Ventures II LP Neuronetics Inc [2019-02-13]
New Leaf Biopharma Opportunities I LP Sierra Oncology Inc [2018-02-14]
New Leaf Ventures I LP Reshape Lifesciences Inc [2018-02-14]
New Leaf Ventures II LP iRhythm Technologies Inc [2017-02-10]
New Leaf Ventures II LP Versartis Inc [2014-04-07]
New Leaf Ventures II LP Chimerix Inc [2014-02-14]
New Leaf Ventures II LP Oxford Immunotec Global PLC [2014-02-14]
New Leaf Ventures I LP Relypsa Inc [2014-02-14]
View All
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesPrivate Equity
Form 3/4/5 Subject 2011 - 2026
New Leaf BPO Associates II LP
New Leaf BPO Management II LLC
Lathi Vijay K
Harpoon Therapeutics Inc
New Leaf Venture Partners LLC
New Leaf Venture Partners LLC
New Leaf Venture Partners LLC
New Leaf Biopharma Opportunities II LP
New Leaf BPO Associates I LP
Deciphera Pharmaceuticals Inc
View All
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Harpoon Therapeutics Inc HARP
Common Stock Warrant (Right to Buy) · derivative
2024-03-11 Disposed to issuer 299,430
Harpoon Therapeutics Inc HARP
Common Stock
2024-03-11 Disposed to issuer 1,463,386
Harpoon Therapeutics Inc HARP
Common Stock Warrant (Right to Buy) · derivative
2024-03-11 Disposed to issuer 686,000
Harpoon Therapeutics Inc HARP
8.000% Series A Redeemable Preferred Stock
2024-03-11 Disposed to issuer 10,000
Harpoon Therapeutics Inc HARP
Common Stock Warrant (Right to Buy) · derivative
2024-03-11 Disposed to issuer 85,750
Harpoon Therapeutics Inc HARP
Common Stock
2024-03-11 Disposed to issuer 395,783
Harpoon Therapeutics Inc HARP
Common Stock Warrant (Right to Buy) · derivative
2023-10-25 Buy 686,000
Harpoon Therapeutics Inc HARP
Common Stock
2023-10-25 Buy 1,372,000
Harpoon Therapeutics Inc HARP
Common Stock
2023-10-25 Buy 171,500
Harpoon Therapeutics Inc HARP
Common Stock Warrant (Right to Buy) · derivative
2023-10-25 Buy 85,750
Harpoon Therapeutics Inc HARP
Common Stock
2021-01-11 Buy 235,294 $17.00 3,999,998
Deciphera Pharmaceuticals Inc DCPH
Common Stock
2019-08-16 Sell 26,108 $37.01 966,257
Deciphera Pharmaceuticals Inc DCPH
Common Stock
2019-08-16 Sell 69,292 $36.54 2,531,930
Deciphera Pharmaceuticals Inc DCPH
Common Stock
2019-08-16 Sell 28,626 $37.01 1,059,448
Deciphera Pharmaceuticals Inc DCPH
Common Stock
2019-08-16 Sell 75,974 $36.54 2,776,090
Deciphera Pharmaceuticals Inc DCPH
Common Stock
2019-08-15 Sell 71,550 $36.09 2,582,240
Deciphera Pharmaceuticals Inc DCPH
Common Stock
2019-08-15 Sell 78,450 $36.09 2,831,261
Principia Biopharma Inc PRNB
Common Stock
2019-08-13 Sell 49,991 $35.00 1,749,685
Principia Biopharma Inc PRNB
Common Stock
2019-08-13 Sell 250,009 $35.00 8,750,315
Harpoon Therapeutics Inc HARP
Common Stock
2019-02-12 Buy 214,285 $14.00 2,999,990
showing 20 of 131 most recent transactions
Comparable Firms State AUM
Auldbrass Partners LP
NY 412.9 M
Auxo Investment Partners LLC
MI 412.0 M
Vortus Investment Advisors LLC
TX 411.7 M
Peloton Equity LLC
CT 409.5 M
Greenridge Equity Partners LLC
TX 408.8 M
Bridge Growth Partners LLC
NY 407.0 M
Generation Partners Management LLC
401.6 M
ROG IX LLC
TX 401.0 M
Palm Peak Capital LLC
FL 400.8 M
ValueQuest Advisers LLC
NY 400.8 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com